Eli Lilly, Boehringer Ingelheim to Study Diabetes Drug Jardiance After Heart Attacks
27 May 2020 - 3:15AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. and Boehringer Ingelheim on Tuesday said
they plan to study whether their diabetes drug Jardiance can
improve outcomes and prevent heart failure in adults with and
without diabetes who have had a heart attack.
The two companies said they will provide funding for the study,
which they will conduct in partnership with the Duke Clinical
Research Institute, part of Duke University's School of
Medicine.
Eli Lilly and Boehringer Ingelheim said the study will include
about 3,300 adults across at least 16 countries who have had an
acute myocardial infarction, more commonly known as a heart
attack.
Indianapolis-based drug maker Eli Lilly and Boehringer
Ingelheim, a family-owned pharmaceutical company based in
Ingelheim, Germany, jointly market Jardiance as part of a 2011
alliance.
The new study is part of a broader clinical program exploring
the impact of Jardiance on patients across the spectrum of
cardio-renal-metabolic conditions, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 26, 2020 13:00 ET (17:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2024 to May 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From May 2023 to May 2024